Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone805-562-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$358.11 million
Profitability
Miscellaneous
Employees1,099
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Inogen (NASDAQ:INGN) Frequently Asked Questions
What is Inogen's stock symbol?
Inogen trades on the NASDAQ under the ticker symbol "INGN."
How were Inogen's earnings last quarter?
Inogen Inc (NASDAQ:INGN) announced its earnings results on Wednesday, August, 7th. The medical technology company reported $0.45 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.50 by $0.05. The medical technology company earned $101.10 million during the quarter, compared to analysts' expectations of $106.88 million. Inogen had a net margin of 11.24% and a return on equity of 13.34%. The company's revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.65 EPS. View Inogen's Earnings History.
When is Inogen's next earnings date?
What guidance has Inogen issued on next quarter's earnings?
Inogen issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $370-375 million, compared to the consensus revenue estimate of $408.89 million.
What price target have analysts set for INGN?
7 analysts have issued 12 month target prices for Inogen's shares. Their forecasts range from $47.00 to $91.00. On average, they anticipate Inogen's stock price to reach $67.60 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price. View Analyst Price Targets for Inogen.
What is the consensus analysts' recommendation for Inogen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen.
What are Wall Street analysts saying about Inogen stock?
Here are some recent quotes from research analysts about Inogen stock:
- 1. Needham & Company LLC analysts commented, "INGN beat consensus revenue and EPS in 4Q18 and management maintained its 2019 guidance for revenue and adjusted EBITDA. The revenue upside was driven by the DTC sales force expansion and was partially offset by slower domestic B2B sales as a single large customer slowed its orders. Gross margin was up Y/Y and beat our estimate while operating margin was down Y/Y and beat our estimate. INGN continues to see the benefit of its DTC sales force expansion as DTC sales grew 50% in 4Q18. We expect the ongoing sales force expansion, new product cycle, and the market shift to POCs to sustain strong growth and drive upside to consensus and we reiterate our Strong Buy rating." (2/27/2019)
- 2. According to Zacks Investment Research, "Inogen outperformed the industry in a year’s time. The company continues to gain from its strong portfolio of portable oxygen concentrators (POC) which has been lending it a competitive edge in the MedTech space. Solid business-to-business revenues also buoy optimism. These apart, the company’s direct-to-consumer unit performed exceedingly well in recent times. Moreover, management remains optimistic about its international revenues, which saw solid growth in Europe in recent times. The raised revenue guidance for 2018 is also an added positive. Inogen issued a bullish guidance for 2019 as well. On the flip side, Inogen’s rental revenues declined on a year-over-year basis in recent times. In fact, the company expects rental revenues to remain down in 2018 and grow modestly in 2019. Rising operating expenses are discouraging as well. In the LTOT market, POC adoption continues to face significant headwinds." (2/14/2019)
Has Inogen been receiving favorable news coverage?
News articles about INGN stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Inogen earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the medical technology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Inogen.
Are investors shorting Inogen?
Inogen saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 4,314,500 shares, an increase of 6.1% from the June 30th total of 4,066,500 shares. Based on an average daily volume of 542,500 shares, the short-interest ratio is currently 8.0 days. Currently, 23.9% of the company's stock are short sold. View Inogen's Current Options Chain.
Who are some of Inogen's key competitors?
Some companies that are related to Inogen include Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC), ConforMIS (CFMS), Lakeland Industries (LAKE), Rewalk Robotics (RWLK), Histogenics (HSGX), Precision Therapeutics (POAI), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Wound Management Technologies (WNDM) and Bionik Laboratories (BNKL).
What other stocks do shareholders of Inogen own?
Who are Inogen's key executives?
Inogen's management team includes the folowing people:
- Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)
- Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 38)
- Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)
- Mr. Bart Sanford, Exec. VP of Operations (Age 53)
- Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40)
Who are Inogen's major shareholders?
Inogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (16.63%), BlackRock Inc. (10.36%), Vanguard Group Inc. (7.76%), AQR Capital Management LLC (4.19%), Janus Henderson Group PLC (2.76%) and Janus Henderson Group PLC (2.76%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.
Which institutional investors are selling Inogen stock?
INGN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Royal Bank of Canada, Morgan Stanley, Waddell & Reed Financial Inc., Kornitzer Capital Management Inc. KS, Chicago Capital LLC, Wells Fargo & Company MN and Price T Rowe Associates Inc. MD. Company insiders that have sold Inogen company stock in the last year include Brenton Taylor, Heath Lukatch, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson and Raymond Huggenberger. View Insider Buying and Selling for Inogen.
Which institutional investors are buying Inogen stock?
INGN stock was acquired by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, AQR Capital Management LLC, Riverbridge Partners LLC, Balyasny Asset Management LLC, Asymmetry Capital Management L.P., Canada Pension Plan Investment Board, Fort Washington Investment Advisors Inc. OH and Summit Creek Advisors LLC. View Insider Buying and Selling for Inogen.
How do I buy shares of Inogen?
Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inogen's stock price today?
One share of INGN stock can currently be purchased for approximately $44.60.
How big of a company is Inogen?
Inogen has a market capitalization of $978.08 million and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen.
What is Inogen's official website?
How can I contact Inogen?
Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]
MarketBeat Community Rating for Inogen (NASDAQ INGN)
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
